Direct-to-Consumer Drug Sales: Analyzing Impact on Pricing

On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Therapeutics and the investor cult that embraces it, both of which performed a painful belly flop this week.

Then, we’ll dish on the growing “pharm to table” movement. That’s the clever buzzphrase bandied around by Big Pharma insiders to promote plans that sell drugs directly to consumers — supposedly at lower costs that will make President Trump happy. Except as our cohost Elaine Chen reported this week, these direct-to-consumer plans championed by Eli Lilly, Novo Nordisk, Bristol Myers Squibb, and others are unlikely to make drugs more affordable. We’ll dig into the details.